CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
As a reminder, CTS will be exhibiting this weekend at the AABB Annual Meeting in San Antonio, T...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...